Ingevity
NGVT
277 hedge funds and large institutions have $2.61B invested in Ingevity in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 104 reducing their positions, and 25 closing their positions.
134% more call options, than puts
Call options by funds: $5.17M | Put options by funds: $2.21M
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
0.37% more ownership
Funds ownership: 92.06% → 92.43% (+0.37%)
0% more funds holding
Funds holding: 277 → 277 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less capital invested
Capital invested by funds: $2.99B → $2.61B (-$383M)
27% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 104
Top Buyers
Top Sellers
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$22.4M |
| 2 |
BlackRock
New York
|
-$12.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$12.2M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$6.94M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.35M |
NGVT Hedge Fund Activity: Q3 2021 in Review
277 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ingevity (NGVT) for Q3 2021, worth a combined $2.61B — down 13% from $2.99B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NGVT positions and 25 closed out — a net gain of 4 holders — while 76 added to existing stakes and 104 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $14.3M. The largest seller was Boston Partners, cutting an estimated $22.4M.
- 277 institutional investors held Ingevity (NGVT) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $2.61B of Ingevity stock for Q3 2021, down 13% quarter-over-quarter.
- 29 funds opened new Ingevity positions in Q3 2021 and 25 closed out, a net change of +4 holders.
- The largest Ingevity buyer in Q3 2021 was Arrowstreet Capital, an estimated $14.3M added.
- The largest Ingevity seller in Q3 2021 was Boston Partners, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2021.